Rafael Holdings announced that its Cyclo Therapeutics subsidiary's Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance on its primary endpoint. However, a prespecified analysis showed a statistically significant benefit in a subgroup, and separate analyses indicated a significant survival benefit, leading the company to remain on track for an NDA submission in Q4 2026.
Rafael Holdings' Cyclo Therapeutics subsidiary reported mixed results for its Phase 3 Trappsol Cyclo study. While the primary endpoint for the overall patient population was not met, a prespecified analysis in a significant subgroup (83% of patients) showed a statistically significant and clinically meaningful benefit. Furthermore, separate overall survival analyses demonstrated a substantial reduction in mortality risk. This creates a complex scenario for investors: the initial headline of a primary endpoint miss is negative, but the strong subgroup and survival data provide a pathway for potential FDA approval, albeit with a longer timeline (NDA in Q4 2026). The stock could see initial downward pressure due to the primary endpoint miss, but the positive secondary data might temper the decline and offer a long-term opportunity if the FDA is receptive to the subgroup and survival findings.